Uplizna
Named-patient access overview. Uplizna is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Uplizna (inebilizumab-cdon) is a humanised anti-CD19 monoclonal antibody developed by Viela Bio, acquired by Horizon Therapeutics, and now part of Amgen. The US Food and Drug Administration approved Uplizna in June 2020 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive, and in April 2025 for generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody-positive.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Uplizna
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Uplizna is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Uplizna in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Uplizna
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.